4.3 Review

Identifying the optimum first-line therapy in BRAF-mutant metastatic melanoma

Related references

Note: Only part of the references are listed.
Article Oncology

First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis

Bastian Schilling et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)

Article Biochemistry & Molecular Biology

Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients

Ryan J. Sullivan et al.

NATURE MEDICINE (2019)

Article Biochemistry & Molecular Biology

Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

Paolo Antonio Ascierto et al.

NATURE MEDICINE (2019)

Article Biochemistry & Molecular Biology

Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma

Antoni Ribas et al.

NATURE MEDICINE (2019)

Article Medicine, General & Internal

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

C. Robert et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Article Medicine, General & Internal

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

J. Larkin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Article Pharmacology & Pharmacy

Efficacy and safety of BRAF inhibitors and anti-CTLA4 antibody in melanoma patientsreal-world data

Marta Polkowska et al.

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2019)

Article Dermatology

Real-world treatment patterns and clinical outcomes in advanced cutaneous melanoma patients in France

B. Sassolas et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2018)

Article Oncology

Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition

Douglas B. Johnson et al.

JOURNAL OF IMMUNOTHERAPY (2017)

Article Medicine, General & Internal

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

J. D. Wolchok et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Article Medicine, General & Internal

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

G. V. Long et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Article Oncology

PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors

Hojabr Kakavand et al.

CLINICAL CANCER RESEARCH (2017)

Article Medicine, General & Internal

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

Antoni Ribas et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)

Article Medicine, General & Internal

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

Caroline Robert et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Article Medicine, General & Internal

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

J. Larkin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Article Cell Biology

Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAFV600E melanoma

Siwen Hu-Lieskovan et al.

SCIENCE TRANSLATIONAL MEDICINE (2015)

Article Medicine, General & Internal

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

G. V. Long et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Article Medicine, General & Internal

Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

James Larkin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Article Oncology

BRAF Inhibition Alleviates Immune Suppression in Murine Autochthonous Melanoma

Shannon M. Steinberg et al.

CANCER IMMUNOLOGY RESEARCH (2014)

Letter Medicine, General & Internal

Hepatotoxicity with Combination of Vemurafenib and Ipilimumab

Antoni Ribas et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Article Oncology

Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma

James S. Wilmott et al.

CLINICAL CANCER RESEARCH (2012)

Article Medicine, General & Internal

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

Paul B. Chapman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

Article Medicine, General & Internal

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

F. Stephen Hodi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)